Tubocurarine chloride

History

Tubocurarine is a naturally occurring mono-quaternary alkaloid obtained from the bark of the Menispermaceous South American plant Chondrodendron tomentosum, a climbing vine known to the European world since the Spanish conquest of South America. Curare had been used as a source of arrow poison by South American natives to hunt animals, and they were able to eat the animals' contaminated flesh subsequently without any adverse effects because tubocurarine cannot easily cross mucous membranes. Thus, tubocurarine is effective only if given parenterally, as demonstrated by Bernard, who also showed that the site of its action was at the neuromuscular junction. Virchow and Munter confirmed the paralyzing action was limited to voluntary muscles.

Etymology

The word curare comes from a word in the Cariban languages. Tubocurarine is so-called because some of the plant extracts designated curare were stored, and subsequently shipped to Europe, in bamboo tubes. Likewise, curare stored in calabash containers was called calabash curare, although this was usually an extract not of Chondrodendron, but of the Strychnos species S. toxifera, containing a different alkaloid, namely toxiferine. Pot curare was generally a mixture of extracts from various genera in the families Menispermaceae and Loganiaceae. The tripartite classification into "tube", "calabash", and "pot" curares early became untenable, due to inconsistencies in the use of the different types of vessels and the complexities of the dart poison recipes themselves.

Use in anesthesia

Griffith and Johnson are credited with pioneering the formal clinical introduction of tubocurarine as an adjunct to anesthetic practice on 23 January 1942, at the Montreal Homeopathic Hospital. In this sense, tubocurarine is the prototypical adjunctive neuromuscular non-depolarizing agent. However, others before Griffith and Johnson had attempted use of tubocurarine in several situations: some under controlled study conditions while others not quite controlled and remained unpublished. Regardless, all in all some 30,000 patients had been given tubocurarine by 1941, although it was Griffith and Johnson's 1942 publication The technique as described by Gray and Halton was widely known as the "Liverpool technique", and became the standard anesthetic technique in England in the 1950s and 1960s for patients of all ages and physical status. Present clinical anesthetic practice still employs the central principle of balanced anesthesia though with some differences to accommodate subsequent technological advances and introductions of new and better gaseous anesthetic, hypnotic and neuromuscular blocking agents, and tracheal intubation, as well as monitoring techniques that were nonexistent in the day of Gray and Halton: pulse oximetry, capnography, peripheral nerve stimulation, noninvasive blood pressure monitoring, etc.

Chemical properties

Structurally, tubocurarine is a benzylisoquinoline derivative. Its structure, when first elucidated in 1948 and for many years, was incorrectly thought to be bis-quaternary: in other words, it was thought to be an N,N-dimethylated alkaloid. In 1970, the correct structure was finally established, showing one of the two nitrogens to be tertiary, actually a mono-N-methylated alkaloid.

Biosynthesis

Tubocurarine biosynthesis involves a radical coupling of the two enantiomers of N-methylcoclaurine. (R) and (S)-N-methylcoclaurine come from a Mannich-like reaction between dopamine and 4-hydroxyphenylacetaldehyde, facilitated by norcoclaurine synthase (NCS). Both dopamine and 4-hydroxyphenylacetaldehyde originate from L-tyrosine. Methylation of the amine and hydroxyl substituents are facilitated by S-adenosyl methionine (SAM). One methyl group is present on each nitrogen atom prior to the radical coupling. The additional methyl group is transferred to form tubocurarine, with its single quaternary N,N-dimethylamino group.

Biological effects

Without intervention, acetylcholine (ACh) in the peripheral nervous system activates skeletal muscles. Acetylcholine is produced in the body of the neuron by choline acetyltransferase and transported down the axon to the synaptic gap. Tubocurarine chloride acts as an antagonist for the nicotinic acetylcholine receptor (nAChr), meaning it blocks the receptor site from ACh. This may be due to the quaternary amino structural motif found on both molecules.

Clinical pharmacology

Unna et al. reported the effects of tubocurarine on humans:

Tubocurarine has a time of onset of around 5 minutes which is relatively slow among neuromuscular-blocking drugs, and has a duration of action of 60 to 120 minutes. It also causes histamine release, now a recognized hallmark of the tetrahydroisoquinolinium class of neuromuscular blocking agents. Histamine release is associated with bronchospasms, hypotension, and salivary secretions, making it dangerous for asthmatics, children, and those who are pregnant or lactating. However, the main disadvantage in the use of tubocurarine is its significant ganglion-blocking effect, that manifests as hypotension, in many patients; this constitutes a relative contraindication to its use in patients with myocardial ischaemia.

Because of the shortcomings of tubocurare, much research effort was undertaken soon after its clinical introduction to find a suitable replacement. The efforts unleashed a multitude of compounds borne from structure-activity relations developed from the tubocurare molecule. Some key compounds that have seen clinical use are identified in the muscle relaxants template box below. Of the many tried as replacements, only a few enjoyed as much popularity as tubocurarine: pancuronium, vecuronium, rocuronium, atracurium, and cisatracurium. Succinylcholine is a widely used muscle relaxant drug which acts by activating, instead of blocking, the ACh receptor.

The potassium channel blocker tetraethylammonium (TEA) has been shown to reverse the effects of tubocurarine. It is thought to do so by increasing ACh release, which counteracts the antagonistic effects of tubocurarine on the ACh receptor.

Use as spider bite treatment

Spiders of the genus Latrodectus have α-latrotoxin in their venom. The most well known spider in this genus is the black widow spider. α-latrotoxin causes the release of neurotransmitters into the synaptic gap, including acetylcholine. Bites are usually not fatal, but do cause a significant amount of pain in addition to muscle spasms. The venom is the most damaging to nerve endings, but the introduction of d-tubocurarine chloride blocks the nAChr, alleviating pain and muscle spasms while an antivenom can be administered.

Toxicology

An individual administered tubocurarine chloride will be unable to move any voluntary muscles, including the diaphragm. A large enough dose will therefore result in death from respiratory failure unless artificial ventilation is initiated. The LD50 for mice and rabbits are 0.13 mg/kg and 0.146 mg/kg intravenously, respectively. It releases histamine and causes hypotension.

References

References

1. (1856). "Analyse physiologie des propriétés des actions de curare et de la nicotine sure systèmes musculaire et nerveux au moyen du curare". Compt. Rend..
2. (1977). "The civilizing of curare: a history of its development and introduction into anesthesiology". Anesthesia and Analgesia.
3. "Definition of CURARE".
4. The Alkaloids: Chemistry and Physiology ed. R.H.F. Manske (Dominion Rubber Research Laboratory Guelph, Ontario) Academic Press Inc., publishers New York 1955 Volume 5: Pharmacology
5. (1942). "The use of curare in general anesthesia". Anesthesiology.
6. (1912). "Ueber die verbindung der lokakanaesthesie und epidurale injektion anesthesiernder losungen bei tabischen magenkrisen". Beitr Klin Chir.
7. (January 1991). "Dr F.P. de Caux--the first user of curare for anesthesia in England". Anaesthesia.
8. (1941). "Curare: a preventive of traumatic complications in electroconvulsive shock therapy". Am J Psychiatry.
9. (October 1984). "An excursion into pharmacology: curare in medicine". Medical History.
10. (1939). "Therapeutic use of curare and erythroidine hydrochloride for spastic and dystonic states". Arch Neurol Psychiatry.
11. (1992). ""Curare". In: Maltby JR, Shephard DAE (Eds.), Harold Griffith – His Life and Legacy". Can J Anaesth.
12. (August 1946). "Curarine with Balanced Anaesthesia". British Medical Journal.
13. (1948). "64. Curare alkaloids. Part VII. Constitution of dextrotubocurarine chloride". J Chem Soc.
14. (1970). "Revision of the structures of (+)-tubocurarine chloride and (+)-chondrocurine". J. Chem. Soc. Chem. Commun..
15. Dewick, P. M. Medicinal Natural Products; a Biosynthetic Approach. 3rd ed.; John Wiley and Sons Ltd.: 2009.
16. (2001). "Basic and clinical pharmacology:Introduction to autonomic pharmacology". The McGraw Hill Companies.
17. (October 2001). "The kinetics of inhibition of nicotinic acetylcholine receptors by (+)-tubocurarine and pancuronium". Molecular Pharmacology.
18. (March 1950). "Evaluation Of Curarizing Drugs in Man". The Journal of Pharmacology and Experimental Therapeutics.
19. (February 1980). "Muscle relaxant drugs". British Journal of Hospital Medicine.
20. (2003). "Pharmacology". Churchill Livingstone.
21. (1976). "Neuromuscular Junction". Springer-Verlag.
22. "''d''-Tubocurarine (Prototype Nondepolarizing Neuromuscular Blocker)".
23. (October 1972). "Neuromuscular blocking and ganglion blocking activities of some acetylcholine antagonists in the cat". The Journal of Pharmacy and Pharmacology.
24. (October 1972). "The immediate cardiovascular effects of pancuronium, alcuronium and tubocurarine in man". Anaesthesia.
25. (March 2001). "alpha-Latrotoxin and its receptors: neurexins and CIRL/latrophilins". Annual Review of Neuroscience.
26. (September 1953). "Black widow spider (Latrodectus mactans) poisoning treated with d-tubocurarine chloride". Annals of Internal Medicine.
27. (December 1956). "3, 6-bis(3-diethylaminopropoxy) pyridazine bismethiodide, a long-acting neuromuscular blocking agent". The Journal of Pharmacology and Experimental Therapeutics.